INSMED Inc (INSM)

↓ Download CSV

CIK 0001104506 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated VA
  • Fiscal year ends Dec 31

In fiscal 2025, INSMED Inc reported revenue of $606.42M, up 66.7% from the prior year. The company ran a net loss, with a net margin of -210.5%. It held $2.26B in total assets against $1.53B in total liabilities.

Key ratios (FY2025)

-205.6%
Operating margin
-210.5%
Net margin
-172.8%
Return on equity
+66.7%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$606.42M$363.71M$305.21M$245.36M$188.46M$164.41M$136.47M$9.84M$0$0
Cost of Revenue$122.94M$85.74M$65.57M$55.13M$44.15M$39.87M$24.21M$2.42M$0$0
Gross Profit$112.25M$7.41M$0
Operating Income-$1.25B-$878.25M-$709.63M-$457.32M-$375.09M-$265.23M-$235.25M-$307.34M-$188.92M-$173.40M
Net Income-$1.28B-$913.77M-$749.57M-$481.53M-$434.65M-$294.09M-$254.34M-$324.28M-$192.65M-$176.27M
EPS (Diluted)$-6.42$-5.57$-5.34$-3.91$-3.88$-3.01$-3.01
Total Assets$2.26B$2.03B$1.33B$1.66B$1.24B$796.15M$742.30M$604.56M$462.05M$237.96M
Total Liabilities$1.53B$1.74B$1.66B$1.57B$833.04M$520.27M$480.62M$396.29M$100.99M$83.47M
Shareholders' Equity$738.98M$285.38M-$331.92M$87.95M$410.47M$275.88M$261.67M$208.27M$361.06M$154.48M
Cash & Equivalents$510.44M$555.03M$482.37M$1.07B$716.78M$532.76M$487.43M$495.07M$381.17M$162.59M
Operating Cash Flow-$935.01M-$683.88M-$536.25M-$400.44M-$363.30M-$219.35M-$250.65M-$257.98M-$159.62M-$146.71M
Capital Expenditures$32.56M$21.92M$13.29M$9.88M$7.29M$6.24M$42.27M$13.09M$3.00M$4.20M
Shares Outstanding199.01M164.04M140.43M123.03M112.11M97.61M84.56M76.89M66.58M61.89M